November Recap: Psychedelic Drug Stocks Index Driven Higher By Incannex

The 5 constituents in the munKNEE Psychedelic Drug Stocks Index had declined 46.5% over the past 3 months only to jump up 30.2% in November thanks in large part to Icannex Healthcare which, with the completion of its re-domiciliation to the U.S. on the last day of November. Below is how their performances ranked, in descending order, in November.

  1. Incannex Healthcare (IXHL): UP 423.0%
  2. Mind Medicine (MNMD): UP 33.6%
  3. Compass Pathways (CMPS): UP 13.0%
  4. Atai Life Sciences (ATAI): DOWN 1.9%
  5. GH Research (GHRS): DOWN 9.7%


Summary

The munKNEE Psychedelic Drug Stocks Index was DOWN 14.3% in August, DOWN another 14.2% in September and DOWN 27.3% in October but was UP 30.2% in November. Were IXHL excluded from the November calculation the Index would only have gone UP 5.3%, but UP never the less. The Index is now only DOWN 12.5% YTD.


More By This Author:

November Recap: 7 Largest American Cannabis MSOs Jumped 40%, On Average
November Recap: 5 Largest Canadian Cannabis Stocks Up 14%, On Average
All About Cybersecurity Stock CrowdStrike And Its Competition

Disclosure: None

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.